Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin - Bausch Health Companies/Curaxis

Next Previous
Drug Profile

Leuprorelin - Bausch Health Companies/Curaxis

Alternative Names: DURIN™ leuprolide implant; DURIN™-leuprolide; Leuprorelin - Bausch Health Companies/Voyager; Leuprorelin - Curaxis/Bausch Health Companies; Leuprorelin - Voyager/Bausch Health Companies; Memryte implant; VP4896

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DURECT Corporation; Voyager Pharmaceutical
  • Developer Curaxis Pharmaceutical Corporation
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Alzheimer's disease

Most Recent Events

  • 11 Sep 2025 DURECT Corporation has been acquired and merged into Bausch Health Companies
  • 23 Sep 2010 Curaxis enters into an equity line agreement with Southridge Partners
  • 19 Aug 2010 Voyager Pharmaceutical completes reverse merger and becomes publicly traded company called Curaxis Pharmaceutical Corporation; funding secured to resume clinical development of leuprolin

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top